Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with normal karyotype and isolated Nucleophosmin-1 (NPM1) mutation: outcome strongly correlates with disease status
2016
Abstrakt
Treatment of acute myeloid leukemia (AML) is generally dictated by the patient's age and performance status and the biological, genetic, and molecular characteristics of the disease. Specific cytogenetic alterations divide AML classification into three risk-based categories: favorable, intermediate and unfavorable.